Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 27
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nat Commun ; 7: 11600, 2016 05 27.
Artigo em Inglês | MEDLINE | ID: mdl-27231034

RESUMO

The V-ATPase is the main regulator of intra-organellar acidification. Assembly of this complex has extensively been studied in yeast, while limited knowledge exists for man. We identified 11 male patients with hemizygous missense mutations in ATP6AP1, encoding accessory protein Ac45 of the V-ATPase. Homology detection at the level of sequence profiles indicated Ac45 as the long-sought human homologue of yeast V-ATPase assembly factor Voa1. Processed wild-type Ac45, but not its disease mutants, restored V-ATPase-dependent growth in Voa1 mutant yeast. Patients display an immunodeficiency phenotype associated with hypogammaglobulinemia, hepatopathy and a spectrum of neurocognitive abnormalities. Ac45 in human brain is present as the common, processed ∼40-kDa form, while liver shows a 62-kDa intact protein, and B-cells a 50-kDa isoform. Our work unmasks Ac45 as the functional ortholog of yeast V-ATPase assembly factor Voa1 and reveals a novel link of tissue-specific V-ATPase assembly with immunoglobulin production and cognitive function.


Assuntos
Disfunção Cognitiva/genética , Síndromes de Imunodeficiência/genética , Hepatopatias/genética , Mutação de Sentido Incorreto , ATPases Vacuolares Próton-Translocadoras/genética , Adolescente , Adulto , Sequência de Aminoácidos , Sequência de Bases , Criança , Pré-Escolar , Disfunção Cognitiva/metabolismo , Saúde da Família , Glicosilação , Humanos , Síndromes de Imunodeficiência/metabolismo , Lactente , Hepatopatias/metabolismo , Masculino , Homologia de Sequência de Aminoácidos , ATPases Vacuolares Próton-Translocadoras/deficiência , Adulto Jovem
3.
J Struct Biol ; 187(3): 254-265, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-25050761

RESUMO

The discovery of pits/caveolae in the plasmalemma advanced the study of macromolecule internalization. "Transcytosis" describes the transport of macromolecular cargo from one front of a polarized cell to the other within membrane-bounded carrier(s), via endocytosis, intracellular trafficking and exocytosis. Clathrin-mediated transcytosis is used extensively by epithelial cells, while caveolae-mediated transcytosis mostly occurs in endothelial cells. The internalization pathways were monitored by various markers, including radioisotopes, nanoparticles, enzymes, immunostains, and fluorophores. We describe an internalization pathway identified using a naturally-occurring biomarker, in vivo assembled ferritin, containing electron-dense iron cores. Iron, an essential trace metal for most living species and iron homeostasis, is crucial for cellular life. Ferritin is a ubiquitous and highly conserved archeoprotein whose main function is to store a reserve iron supply inside the cytoplasm in a non-toxic form. Ferritin is present in all organisms which have a metabolic requirement for iron and in even in organisms whose taxonomic rank is very low. The newborns of the blind mole, Spalax ehrenbergi, are born and live in a hypoxic environment and have significant iron overload in their liver and heart, but their iron metabolism has not been previously studied. These newborns, which are evolutionarily adapted to fluctuations in the environmental oxygen, have a unique ability to sequester transplacental iron and store it in ferritin without any signs of iron toxicity. Using the ferrihydrite cores of ferritin, we were able to monitor the ferritin internalization from portals of its entry into the cytosol of hepatocytes and cardiomyocytes and into the lysosomes.


Assuntos
Biomarcadores/metabolismo , Endocitose/fisiologia , Ferritinas/metabolismo , Substâncias Macromoleculares/metabolismo , Transdução de Sinais/fisiologia , Animais , Animais Recém-Nascidos , Compostos Férricos/química , Compostos Férricos/metabolismo , Ferritinas/química , Ferritinas/ultraestrutura , Hepatócitos/metabolismo , Hepatócitos/ultraestrutura , Hipóxia , Espaço Intracelular/metabolismo , Ferro/química , Fígado/citologia , Fígado/metabolismo , Fígado/ultraestrutura , Microscopia Eletrônica de Transmissão , Miocárdio/citologia , Miocárdio/metabolismo , Miocárdio/ultraestrutura , Miócitos Cardíacos/metabolismo , Miócitos Cardíacos/ultraestrutura , Spalax
4.
Ultrastruct Pathol ; 37(5): 293-303, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24047346

RESUMO

The prevalence of fatty liver is rising not only in adults but also in children and adolescents. The authors describe the ultrastructure of 12 biopsies from 10 males and 2 females aged 7-18 years. All subjects had fatty liver by ultrasonography and were overweight or obese according to BMI classification. They all had elevated aminotransferases and/or lipid/cholesterol levels, ultimately confirmed by biopsy. Steatosis was mild in 2, moderate in 3, and severe in 7 cases. Nonalcoholic steatohepatitis was diagnosed in 7 and nonalcoholic fatty liver disease in 5 patients. Lipolysosomes, identified in all 12 biopsies, were defined as fat droplets surrounded by a trilaminar membrane and lipofuscin-like deposits within or adjacent to the enveloping membrane. The lysosome marker CD68 revealed lysosomal activity in all lipolysosomes identified by electron microscopy. The ultrastructural features, here illustrated in diverse human biopsies, enabled lipolysosome classification in 3 types: monolocular (type I), multilocular (type II), and giant multilocular (type III). Type II, previously described in some conditions with abnormal lipid metabolism, was found in all biopsies, though with variable frequency. Type III was observed only in severe steatosis and associated with prominent connective tissue and conspicuous lipofuscin deposits. These new findings demonstrate the presence of lipolysosomes in a variety of fatty livers, in conditions hitherto unknown, in relation to the severity of steatosis, fibrogenic process, autophagy, lipolysis, and lipofuscin formation.


Assuntos
Fígado Gorduroso/patologia , Lipídeos/análise , Fígado/ultraestrutura , Organelas/ultraestrutura , Terminologia como Assunto , Adolescente , Antígenos CD/análise , Antígenos de Diferenciação Mielomonocítica/análise , Biomarcadores/análise , Biópsia , Criança , Fígado Gorduroso/etiologia , Fígado Gorduroso/metabolismo , Feminino , Humanos , Lipofuscina/análise , Fígado/química , Lisossomos/química , Lisossomos/ultraestrutura , Masculino , Microscopia Eletrônica de Transmissão , Hepatopatia Gordurosa não Alcoólica , Organelas/química , Organelas/classificação , Obesidade Infantil/complicações , Índice de Gravidade de Doença
5.
Am J Med Genet A ; 161A(9): 2204-15, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23918762

RESUMO

3-Methylglutaconic aciduria (3-MGCA) type IV is defined as a heterogeneous group of inborn errors featuring in common 3-MGCA and associated with primary mitochondrial dysfunction leading to a spectrum of multisystem conditions. We studied four patients who presented at birth with a clinical picture simulating a primary mitochondrial hepatic disorder consistent with the MEGDEL syndrome including 3-MGCA, sensorineural deafness, encephalopathy and a brain magnetic resonance imaging with signs of Leigh disease. All affected children displayed biochemical features consistent with mitochondrial OXPHOS dysfunction including hepatic mitochondrial DNA depletion in one patient. Homozygosity mapping identified a candidate locus on 6q25.2-6q26. Using whole exome sequencing, we identified two novel homozygous mutations in SERAC1 recently reported to harbor mutations in MEGDEL syndrome. Both mutations were found to lead to decreased or absent expression of SERAC1. The present findings indicate that infantile hepatopathy is a cardinal feature of MEGDEL syndrome. We thus propose to rename the disease MEGDHEL syndrome.


Assuntos
Anormalidades Múltiplas/genética , Hidrolases de Éster Carboxílico/genética , Perda Auditiva Neurossensorial/genética , Doença de Leigh/genética , Hepatopatias/genética , Erros Inatos do Metabolismo/genética , Doenças Mitocondriais/genética , Mutação , Anormalidades Múltiplas/diagnóstico , Encéfalo/patologia , Estudos de Casos e Controles , Mapeamento Cromossômico , Consanguinidade , Análise Mutacional de DNA , Complexo de Proteínas da Cadeia de Transporte de Elétrons/metabolismo , Perda Auditiva Neurossensorial/diagnóstico , Homozigoto , Humanos , Recém-Nascido , Doença de Leigh/diagnóstico , Fígado/patologia , Fígado/ultraestrutura , Hepatopatias/diagnóstico , Imageamento por Ressonância Magnética , Masculino , Erros Inatos do Metabolismo/diagnóstico , Repetições de Microssatélites/genética , Mitocôndrias/patologia , Mitocôndrias/ultraestrutura , Doenças Mitocondriais/diagnóstico , Linhagem , Polimorfismo de Nucleotídeo Único , Síndrome
6.
BMC Biol ; 11: 91, 2013 Aug 09.
Artigo em Inglês | MEDLINE | ID: mdl-23937926

RESUMO

BACKGROUND: Subterranean blind mole rats (Spalax) are hypoxia tolerant (down to 3% O2), long lived (>20 years) rodents showing no clear signs of aging or aging related disorders. In 50 years of Spalax research, spontaneous tumors have never been recorded among thousands of individuals. Here we addressed the questions of (1) whether Spalax is resistant to chemically-induced tumorigenesis, and (2) whether normal fibroblasts isolated from Spalax possess tumor-suppressive activity. RESULTS: Treating animals with 3-Methylcholantrene (3MCA) and 7,12-Dimethylbenz(a) anthracene/12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA), two potent carcinogens, confirmed Spalax high resistance to chemically induced cancers. While all mice and rats developed the expected tumors following treatment with both carcinogens, among Spalax no tumors were observed after DMBA/TPA treatment, while 3MCA induced benign fibroblastic proliferation in 2 Spalax individuals out of12, and only a single animal from the advanced age group developed malignancy 18 months post-treatment. The remaining animals are still healthy 30 months post-treatment. In vitro experiments showed an extraordinary ability of normal Spalax cultured fibroblasts to restrict malignant behavior in a broad spectrum of human-derived and in newly isolated Spalax 3MCA-induced cancer cell lines. Growth of cancer cells was inhibited by either direct interaction with Spalax fibroblasts or with soluble factors released into culture media and soft agar. This was accompanied by decreased cancer cell viability, reduced colony formation in soft agar, disturbed cell cycle progression, chromatin condensation and mitochondrial fragmentation. Cells from another cancer resistant subterranean mammal, the naked mole rat, were also tested for direct effect on cancer cells and, similar to Spalax, demonstrated anti-cancer activity. No effect on cancer cells was observed using fibroblasts from mouse, rat or Acomys. Spalax fibroblast conditioned media had no effect on proliferation of noncancerous cells. CONCLUSIONS: This report provides pioneering evidence that Spalax is not only resistant to spontaneous cancer but also to experimentally induced cancer, and shows the unique ability of Spalax normal fibroblasts to inhibit growth and kill cancer cells, but not normal cells, either through direct fibroblast-cancer cell interaction or via soluble factors. Obviously, along with adaptation to hypoxia, Spalax has evolved efficient anti-cancer mechanisms yet to be elucidated. Exploring the molecular mechanisms allowing Spalax to survive in extreme environments and to escape cancer as well as to kill homologous and heterologous cancer cells may hold the key for understanding the molecular nature of host resistance to cancer and identify new anti-cancer strategies for treating humans.


Assuntos
Resistência à Doença/imunologia , Neoplasias/imunologia , Spalax/imunologia , 9,10-Dimetil-1,2-benzantraceno , Animais , Carcinógenos/toxicidade , Carcinoma Hepatocelular/patologia , Ciclo Celular/efeitos dos fármacos , Morte Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Forma Celular , Sobrevivência Celular/efeitos dos fármacos , Técnicas de Cocultura , Meios de Cultivo Condicionados/farmacologia , Fragmentação do DNA/efeitos dos fármacos , Fibroblastos/efeitos dos fármacos , Fibroblastos/metabolismo , Fibroblastos/patologia , Fibrossarcoma/patologia , Humanos , Neoplasias Hepáticas/patologia , Camundongos , Dinâmica Mitocondrial/efeitos dos fármacos , Neoplasias/patologia , Ratos , Acetato de Tetradecanoilforbol , Ensaio Tumoral de Célula-Tronco
7.
J Neural Transm (Vienna) ; 120(1): 37-48, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22446839

RESUMO

Iron accumulation and iron-related oxidative stress are involved in several pathological conditions and provide a rationale for the development of iron chelators as novel promising therapeutic strategies. Thus, we have recently synthesized multifunctional non-toxic, brain permeable iron chelating compounds, M30 and HLA20, possessing the neuroprotective N-propargyl moiety of the anti-Parkinsonian drug, monoamine oxidase (MAO)-B inhibitor, rasagiline and the antioxidant-iron chelating moiety of an 8-hydroxyquinoline derivative of the iron chelator, VK28. Here, we examined the hepatic regulatory effects of these novel compounds using two experimental approaches: chelation activity and glucose metabolism parameters. The present study demonstrated that M30 and HLA20 significantly decreased intracellular iron content and reduced ferritin expression levels in iron-loaded hepatoma Hep3B cells. In electron microscopy analysis, M30 was shown to reduce the electron-dense deposits of siderosomes by ~30 %, as well as down-regulate cytosolic ferritin particles observed in iron-overloaded cells. In vivo studies demonstrated that M30 administration (1 mg/kg, P.O. three times a week) reduced hepatic ferritin levels; increased hepatic insulin receptor and glucose transporter-1 levels and improved glucose tolerance in C57BL/6 mice and in a mouse model of type-2 diabetes, the ob/ob (leptin(-/-)). The results clearly indicate that the novel multifunctional drugs, especially M30, display significant capacity of chelating intracellular iron and regulating glucose metabolism parameters. Such effects can have therapeutic significance in conditions with abnormal local or systemic iron metabolism, including neurological diseases.


Assuntos
Glucose/metabolismo , Quelantes de Ferro/farmacologia , Ferro/metabolismo , Inibidores da Monoaminoxidase/farmacologia , Fármacos Neuroprotetores/farmacologia , Animais , Benzofuranos , Carcinoma Hepatocelular/patologia , Linhagem Celular Tumoral , Relação Dose-Resposta a Droga , Compostos Férricos/farmacologia , Ferritinas/metabolismo , Teste de Tolerância a Glucose , Humanos , Hidroxiquinolinas/química , Hidroxiquinolinas/farmacologia , Quelantes de Ferro/química , Leptina/deficiência , Fígado/efeitos dos fármacos , Fígado/metabolismo , Fígado/ultraestrutura , Masculino , Camundongos , Camundongos Transgênicos , Microscopia Eletrônica de Transmissão , Fármacos Neuroprotetores/química , Piperazinas/química , Piperazinas/farmacologia , Compostos de Amônio Quaternário/farmacologia , Quinolinas
8.
Free Radic Biol Med ; 53(4): 779-86, 2012 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-22749805

RESUMO

The haptoglobin (Hp) genotype is a major determinant of progression of nephropathy in individuals with diabetes mellitus (DM). The major function of the Hp protein is to bind and modulate the fate of extracorpuscular hemoglobin and its iron cargo. We have previously demonstrated an interaction between the Hp genotype and the DM on the accumulation of iron in renal proximal tubule cells. The primary objective of this study was to determine the intracellular localization of this iron in the proximal tubule cell and to assess its potential toxicity. Transmission electron microscopy demonstrated a marked accumulation of electron-dense deposits in the lysosomes of proximal tubules cells in Hp 2-2 DM mice. Energy-dispersive X-ray spectroscopy and electron energy loss spectroscopy were used to perform elemental analysis of these deposits and demonstrated that these deposits were iron rich. These deposits were associated with lysosomal membrane lipid peroxidation and loss of lysosomal membrane integrity. Vitamin E administration to Hp 2-2 DM mice resulted in a significant decrease in both intralysosomal iron-induced oxidation and lysosomal destabilization. Iron-induced renal tubular injury may play a major role in the development of diabetic nephropathy and may be a target for slowing the progression of renal disease.


Assuntos
Diabetes Mellitus Experimental/complicações , Nefropatias Diabéticas/genética , Haptoglobinas/genética , Túbulos Renais Proximais/patologia , Lisossomos/patologia , Animais , Antioxidantes/farmacologia , Antioxidantes/uso terapêutico , Diabetes Mellitus Experimental/tratamento farmacológico , Diabetes Mellitus Experimental/metabolismo , Nefropatias Diabéticas/tratamento farmacológico , Nefropatias Diabéticas/metabolismo , Genótipo , Membranas Intracelulares , Ferro/metabolismo , Túbulos Renais Proximais/efeitos dos fármacos , Túbulos Renais Proximais/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Lisossomos/efeitos dos fármacos , Lisossomos/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Oxirredução , Estresse Oxidativo , Vitamina E/farmacologia , Vitamina E/uso terapêutico , beta-N-Acetil-Hexosaminidases/metabolismo
9.
FEBS J ; 278(18): 3494-507, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21790999

RESUMO

A multikinase inhibitor of the Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway, sorafenib, is increasingly being used in the management of hepatocellular carcinoma, and its combination with conventional chemotherapeutics has stimulated particular interest. Although the combination of sorafenib with doxorubicin (DOX) is presently being investigated in a phase III randomized trial, little is known about the molecular mechanisms of their interaction. Because DOX causes cell death through upregulation of the MEK/ERK pathway, and sorafenib has an opposite influence on the same cascade, we hypothesized that co-treatment with these drugs may lead to an antagonistic effect. DOX treatment arrested proliferation and induced autophagic cell death in Hep3B cells, whereas apoptotic changes were not conspicuous. Sorafenib alone affected viability and caused massive mitochondrial degradation. However, when added together with DOX, sorafenib facilitated cell cycle progression, increased survival, and reduced autophagy. To evaluate the molecular mechanisms of this phenomenon, we examined the expression of ERK1/2, protein kinase B (Akt), and cyclin D1, as well as the members of Bcl-2 family. ERK1/2 activation induced by DOX was suppressed by sorafenib. Similarly, ERK targeting with the selective inhibitor U0126 impaired DOX-induced toxicity. Treatment with sorafenib, either alone or in combination with DOX, resulted in Akt activation. The role of sorafenib-induced degradation of cyclin D1 in the suppression of DOX efficiency is discussed. In conclusion, MEK/ERK counteraction, stimulation of survival via Akt and dysregulation of cyclin D1 could contribute to the escape from DOX-induced autophagy and thus promote cancer cell survival. The use of MEK/ERK inhibitors in combination with chemotherapeutics, intended to enhance anticancer efficacy, requires the consideration of possible antagonistic effects.


Assuntos
Antibióticos Antineoplásicos/antagonistas & inibidores , Autofagia/efeitos dos fármacos , Benzenossulfonatos/farmacologia , Carcinoma Hepatocelular/tratamento farmacológico , Doxorrubicina/antagonistas & inibidores , MAP Quinases Reguladas por Sinal Extracelular/antagonistas & inibidores , Inibidores de Proteínas Quinases/farmacologia , Piridinas/farmacologia , Antibióticos Antineoplásicos/farmacologia , Antineoplásicos/farmacologia , Carcinoma Hepatocelular/metabolismo , Carcinoma Hepatocelular/ultraestrutura , Ciclo Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Ciclina D1/metabolismo , Doxorrubicina/farmacologia , Ativação Enzimática/efeitos dos fármacos , MAP Quinases Reguladas por Sinal Extracelular/química , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Humanos , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/ultraestrutura , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Mitocôndrias Hepáticas/efeitos dos fármacos , Proteína de Sequência 1 de Leucemia de Células Mieloides , Niacinamida/análogos & derivados , Compostos de Fenilureia , Fosforilação/efeitos dos fármacos , Processamento de Proteína Pós-Traducional/efeitos dos fármacos , Proteínas Proto-Oncogênicas c-akt/agonistas , Proteínas Proto-Oncogênicas c-akt/metabolismo , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Sorafenibe
10.
J Neural Transm (Vienna) ; 118(3): 329-35, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21318635

RESUMO

The iron storage proteins, ferritin and hemosiderin, enable electron microscopic visualization thanks to their electron-dense iron content, which is not present in other compounds involved in transport or metabolism of iron such as transferrin, lactoferrin, or hemoglobin. It is this electron density which contributed to the unraveling of stages in absorption, transport, deposition, storage, and release of iron. In recent years, additional methods of investigation have further supported the information achieved by the ultrastructural studies. Even while using new analytical methods, the seminal morphological observations remain valid for understanding the role of iron in health and disease. In this review, we will illustrate a few basic findings of electron microscopy in humans, experimental animals, and cell cultures. The importance of H chain ferritin as a transporter across the blood-brain barrier is just an example of a new role revealed for an "old" storage protein, explaining some controversial observations on the presence of iron in the brain.


Assuntos
Transporte Biológico/fisiologia , Barreira Hematoencefálica/metabolismo , Ferro/metabolismo , Animais , Encéfalo/metabolismo , Ferritinas/metabolismo , Ferritinas/ultraestrutura , Hemossiderina/metabolismo , Humanos , Transferrina/metabolismo
11.
Eur J Med Genet ; 54(3): 209-13, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21145995

RESUMO

1p36 deletion is the most common terminal deletion syndrome with an estimated occurrence of 1:5000 live births. The deletion is of variable size. It usually involves less than 10 Mb in the 1pter-1p36.23 interval. Variability of the phenotype is partially related to the extent of the deletion. Some children with a 1p36 deletion were reported with obesity and hyperphagia, raising the question of possible phenotypic overlap with Prader-Willi syndrome. Correlation between presence of obesity and the size of the deletion has only been documented in one case. We report a 11-year-old girl with 1p36 deletion and the classical dysmorphological features. In late infancy, she developed an uncontrolled voracious appetite, overweight, truncal obesity and elevated serum transaminases. Liver biopsy disclosed severe steatosis. The hepatocytes contained accumulation of lipofuscins. Lipolysosomes were abnormally numerous and extremely enlarged. These features have not been previously reported in 1p36 deletion. Oligonucleotide-based microarray analysis showed a subtelomeric 2.2 Mb deletion at 1p36.33p36.32. This suggests that this chromosome segment is a critical region for obesity and hyperphagia. The accumulation in the liver with abnormal ultrastructure may be an additional feature of this form of syndromal obesity. 1p36 deletion syndrome should be considered in patients with obesity, hyperphagia and liver fat accumulation.


Assuntos
Deleção Cromossômica , Transtornos Cromossômicos/genética , Cromossomos Humanos Par 1/genética , Fígado Gorduroso/metabolismo , Criança , Transtornos Cromossômicos/metabolismo , Transtornos Cromossômicos/patologia , Fígado Gorduroso/patologia , Feminino , Hepatócitos/metabolismo , Hepatócitos/patologia , Hepatócitos/ultraestrutura , Humanos , Hibridização in Situ Fluorescente , Lipofuscina/metabolismo , Lisossomos/metabolismo , Lisossomos/ultraestrutura , Microscopia Eletrônica , Obesidade/patologia , Síndrome
12.
Ultrastruct Pathol ; 34(3): 117-25, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-20455660

RESUMO

Although there has been substantial progress in the identification of diarrheal diseases in infancy and childhood, electron microscopy may be still required for establishing diagnosis, staging, and response to therapy. This review describes severe conditions in which histopathologic examination alone cannot provide a firm diagnosis needed for therapeutic decisions. Microvillus inclusion disease, in its several variants, typifies this category. In certain forms of congenital disorders of glycosylation with gastrointestinal involvement, electron microscopic diagnosis is helpful. Among disorders due to abnormal immune-mediated reactions, celiac disease and cow's milk protein intolerance show fine structural changes of both diagnostic and staging value. Likewise, protein-losing enteropathies, including lymphangectasia, reveal information on the nature and extent of intestinal involvement.


Assuntos
Enterócitos/ultraestrutura , Enteropatias/diagnóstico , Microscopia Eletrônica de Transmissão/métodos , Doença Celíaca/diagnóstico , Criança , Pré-Escolar , Infecções por Citomegalovirus/diagnóstico , Diarreia Infantil/patologia , Humanos , Corpos de Inclusão/ultraestrutura , Lactente , Recém-Nascido , Enteropatias/congênito , Mucosa Intestinal/patologia , Intestino Delgado/patologia , Linfangiectasia Intestinal/diagnóstico , Microvilosidades/ultraestrutura , Esteatorreia/diagnóstico
13.
Ultrastruct Pathol ; 31(3): 189-97, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17613998

RESUMO

A new group of genetic diseases characterized by defective glycoprotein biosynthesis was recently described. Transferrin isoelectric focusing enabled identification of several types of patients with congenital disorders of glycosylation (CDG). The authors report on the liver involvement in two siblings with CDG type Ix presenting with failure to thrive and hypertransaminasemia who developed cardiomyopathy. In the initially affected infant, liver biopsy at 13 months of age showed increased periportal cellularity, steatosis, and mild fibrosis. Ultrastructurally, the hepatocytes displayed numerous myelinosomes, mostly with a pericanalicular polarization. No myelinosomes were seen in the bile canaliculi, Kupffer cells, and sinusoidal lining cells. Focal large droplet steatosis was also noticed. These ultrastructural findings represent another diagnostic element in this heterogenic group of conditions. Electron microscopy can contribute to the elucidation of hypertransaminasemia and differentiate some types of CDG from other lysosomal diseases.


Assuntos
Defeitos Congênitos da Glicosilação/patologia , Hepatócitos/ultraestrutura , Fígado/ultraestrutura , Cardiomiopatias/genética , Cardiomiopatias/patologia , Pré-Escolar , Defeitos Congênitos da Glicosilação/genética , Defeitos Congênitos da Glicosilação/metabolismo , Consanguinidade , Genes Recessivos , Glicosilação , Hepatócitos/metabolismo , Humanos , Lactente , Focalização Isoelétrica , Fígado/metabolismo , Masculino , Microscopia Eletrônica de Transmissão , Irmãos , Transferrina/análise
14.
Ultrastruct Pathol ; 31(3): 173-88, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17613997

RESUMO

Microvillous inclusion disease (MVID) is a congenital, usually neonatal, autosomal recessive condition manifested by severe, prolonged secretory diarrhea. Intestinal biopsies reveal extensive microvilli abnormalities, typical inclusions and vesicles mainly of the apical-luminal enterocytes and colonocytes. Although diagnosis can be suspected by special stains of the mucosa (PAS, CD10), the definitive diagnosis, recommended in view of potential intestinal transplantation, requires electron microscopy. In view of the marked variability of ultrastructural changes, extensive illustration is considered valuable for diagnosis. While the pathogenesis is still unknown, a number of images illustrate the suspected "arrested-trafficking" hypothesis of microvillous abnormalities. Others micrographs support the "engulfing" mechanism of inclusion formation. The electron micrographs should help ultrastructural diagnosis in this heterogeneous disease and can confirm diagnosis even in the absence of the typical inclusions.


Assuntos
Diarreia Infantil/patologia , Enterócitos/ultraestrutura , Corpos de Inclusão/ultraestrutura , Enteropatias/patologia , Microvilosidades/ultraestrutura , Diarreia Infantil/complicações , Diarreia Infantil/congênito , Duodeno/patologia , Feminino , Humanos , Lactente , Recém-Nascido , Enteropatias/complicações , Enteropatias/congênito , Jejuno/patologia , Masculino , Microscopia Eletrônica de Transmissão/métodos
15.
Pediatr Neurol ; 36(6): 411-3, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17560505

RESUMO

We report the first known case in Israel of a patient with an early childhood onset of ceroid-lipofuscinosis who is homozygous to a mutation of the CLN8 gene. This patient further expands the clinical varieties of CLN8, initially reported in Finland and Turkey and recently in Italy. The ultrastructural pathology of a skin biopsy specimen revealed abundant typical fingerprint profiles, but rare granular osmiophilic bodies and curvilinear structures. Sequencing of exon 3 of the CLN8 gene revealed a novel C>G missense mutation at a conserved amino acid glutamine 256 to glutamic acid. Our findings further raise the possibility of the existence of a Mediterranean CLN8 variant.


Assuntos
Proteínas de Membrana/genética , Mutação de Sentido Incorreto , Lipofuscinoses Ceroides Neuronais/genética , Pré-Escolar , Células Epiteliais/patologia , Células Epiteliais/ultraestrutura , Homozigoto , Humanos , Israel , Masculino , Região do Mediterrâneo , Microscopia Eletrônica , Lipofuscinoses Ceroides Neuronais/patologia , Fenótipo
16.
J Pharmacol Exp Ther ; 322(3): 1013-22, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17526808

RESUMO

Doxorubicin (DOX) is a widely used chemotherapeutic drug for human hepatocellular carcinoma (HCC). A major limitation to its effectiveness is the development of multidrug resistance of cancer cells. In clinical trials, patients with advanced HCC were treated with high-dose acetaminophen (HAAP) in an effort to improve the antitumor activity of chemotherapeutics. In this study, we investigated the effect of concomitant treatment of DOX and HAAP on hepatoma-derived HepG2 cells. Viability, cell cycle distribution, and ultrastructure were examined. Unexpectedly, HAAP, when added to DOX-exposed cells, increased cell viability, released cell cycle arrest, and decreased apoptosis. To elucidate the mechanisms by which HAAP reduces the DOX lethal effect to HepG2 cells, we investigated the multidrug resistance P-glycoprotein (P-gp) and p44/42-mitogen-activated protein kinase (MAPK) pathways. The P-gp function was enhanced by DOX and HAAP, and it was further stimulated during combined treatment, leading to decreased DOX retention. Verapamil (VRP), when added to DOX + HAAP exposure, increased DOX accumulation and restored DOX-induced toxicity. The increased phospho-p44/42-MAPK level in DOX-exposed cells was inhibited by HAAP. In addition, suppression of p44/42 activation by the p44/42-MAPK inhibitor 2'-amino-3'-methoxyflavone (PD98059) blocked DOX-induced apoptosis. These findings suggest that the antagonistic effect of concomitant DOX + HAAP treatment occurs as a result of interactive stimulation of P-gp, generating decreased intracellular drug concentrations. Furthermore, inhibition of the p44/42-MAPK phosphorylation by HAAP could abolish the DOX-induced cell death pathway. Thus, combined treatment by DOX + HAAP, intended to improve chemotherapeutic efficacy, could have an opposite effect facilitating cancer cell survival.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/fisiologia , Acetaminofen/farmacologia , Carcinoma Hepatocelular/tratamento farmacológico , Doxorrubicina/farmacologia , Proteína Quinase 1 Ativada por Mitógeno/metabolismo , Proteína Quinase 3 Ativada por Mitógeno/metabolismo , Carcinoma Hepatocelular/patologia , Morte Celular , Linhagem Celular Tumoral , Interações Medicamentosas , Humanos , Sistema de Sinalização das MAP Quinases
17.
Lab Invest ; 87(2): 182-8, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17179957

RESUMO

Antibacterial therapy does not fully protect against anthrax because of severe systemic intoxication. Lysosomal processing of anthrax lethal toxin (LTX) is a key event in the disease pathogenesis, and agents interfering with this process, like chloroquine (CQ), may have practical applications. Although LTX is known to induce T-cell suppression, precise mechanisms of this phenomenon are not completely characterized. In the present study, we investigated alterations of lymphocyte ultrastructure caused by LTX and associated with favorable effect of CQ on the LTX-related dysfunction. Peripheral blood lymphocytes were activated via CD3 crosslinking in the presence or absence of LTX and CQ, and examined by transmission electron microscopy, flow cytometry and immunoblotting. Crosslinking of CD3 induced ultrastructural signs of lymphocyte activation, mostly disappeared after LTX treatment. The cell ultrastructure was well preserved in LTX-treated cells, despite dose- and time-dependent inhibition of T-cell function associated with impaired activation of mitogen-activated protein kinase. Regardless of intracellular signaling abnormalities, LTX did not decrease T-cell viability. CQ restored expression of CD69 (P<0.001) and improved phosphorylation of p38 (P=0.022) in LTX-exposed T lymphocytes. The exposure of cells to CQ, with or without LTX, led to appearance of many phagolysosomes with heterogeneous content, possibly representing unprocessed internalized material. In conclusion, LTX suppressed T-cell functions, but did not affect the viability and caused no ultrastructural damage. Ultrastructural observations indicated that CQ reduced harmful effects of LTX, possibly by interfering with lysosomal activity.


Assuntos
Antígenos de Bactérias/toxicidade , Toxinas Bacterianas/toxicidade , Cloroquina/farmacologia , Linfócitos T/efeitos dos fármacos , Linfócitos T/ultraestrutura , Análise de Variância , Citometria de Fluxo , Humanos , Immunoblotting , Microscopia Eletrônica de Transmissão
18.
Basic Clin Pharmacol Toxicol ; 99(3): 213-24, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16930294

RESUMO

Acetaminophen overdose causes severe hepatic failure. Although the mechanisms of acetaminophen hepatotoxicity have been well investigated, little is known about the involvement of the P-glycoprotein in acetaminophen transport and toxicity. P-Glycoprotein is a membrane efflux pump, playing a significant role in regulating absorption, excretion, and tissue distribution of many drugs. To evaluate the contribution of P-glycoprotein transporter in the course of acetaminophen-induced toxicity, HepG2 and Hep3B cells with different P-glycoprotein expression and activity, were treated by acetaminophen (1-10 mM) for different time periods, with or without the P-glycoprotein inhibitor verapamil. P-Glycoprotein activity was determined by rhodamine 123 efflux assay and western blot analysis. To assess the acetaminophen-induced toxicity and effect of verapamil, we investigated cellular redox status, phosphatidylserine externalization, nuclear fragmentation and ultrastructural changes. Verapamil markedly enhanced acetaminophen-induced oxidative damage and cell death. Moreover, verapamil revealed acetaminophen toxicity even at subtoxic levels. High acetaminophen concentrations increased P-glycoprotein activity and content in both HepG2 and Hep3B cells. These observations suggest the involvement of P-glycoprotein in acetaminophen transport. Notwithstanding the differences of the investigated hepatoma cell lines in P-glycoprotein function, acetaminophen-induced toxicity was similar, possibly due to different functions of drug-metabolizing systems. We conclude that acetaminophen is a P-glycoprotein substrate and P-glycoprotein is involved in acetaminophen transport and toxicity in HepG2 and Hep3B cells. This study establishes the fact that acetaminophen can modulate P-glycoprotein in tumour cells, suggesting that its routine use in cancer patients in combination with anticancer drugs, may influence the result of chemotherapy.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Acetaminofen/toxicidade , Carcinoma Hepatocelular/metabolismo , Carcinoma Hepatocelular/patologia , Resistência a Medicamentos , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Acetaminofen/metabolismo , Antineoplásicos/farmacologia , Morte Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Relação Dose-Resposta a Droga , Interações Medicamentosas , Regulação Neoplásica da Expressão Gênica , Humanos , Estresse Oxidativo/efeitos dos fármacos , Verapamil/farmacologia
20.
Acta Pharmacol Sin ; 27(3): 259-72, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16490160

RESUMO

With the increasing incidence of drug-induced liver disease, attempts are being made to better understand the mechanisms behind these frequently life-endangering reactions. Analgesics and anti-inflammatory drugs are a major group exhibiting hepatotoxicity. We review research relating to these reactions, focusing on ultrastructural findings, which may contribute to the comprehension and possible avoidance of drug-induced liver disease. We also present some original observations on clinical material and cultured cells exposed to acetaminophen alone or in combination with the antioxidant N-acetylcysteine or the P-glycoprotein inhibitor verapamil.


Assuntos
Analgésicos não Narcóticos , Anti-Inflamatórios não Esteroides , Hepatócitos/ultraestrutura , Hepatopatias/patologia , Fígado/ultraestrutura , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/antagonistas & inibidores , Acetaminofen/efeitos adversos , Acetaminofen/toxicidade , Acetilcisteína/efeitos adversos , Acetilcisteína/toxicidade , Analgésicos não Narcóticos/efeitos adversos , Analgésicos não Narcóticos/toxicidade , Animais , Anti-Inflamatórios não Esteroides/efeitos adversos , Anti-Inflamatórios não Esteroides/toxicidade , Antioxidantes/efeitos adversos , Antioxidantes/toxicidade , Aspirina/efeitos adversos , Aspirina/toxicidade , Linhagem Celular Tumoral , Doença Hepática Induzida por Substâncias e Drogas , Overdose de Drogas , Humanos , Fígado/patologia , Neoplasias Hepáticas/patologia , Neoplasias Hepáticas/ultraestrutura , Verapamil/efeitos adversos , Verapamil/toxicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...